Antibody therapies are rapidly transforming the treatment landscape of non-Hodgkin lymphoma (NHL). Since the development of rituximab as an anti-CD20 antibody, there has been an intense research interest in antibody-based therapeutic approaches. The use of antibody-drug conjugates, monoclonal antibodies, and bispecific antibodies are increasingly being investigated in clinical trials for the treatment of NHL, particularly in diffuse large B-cell lymphoma (DLBCL) and in the relapsed/refractory setting, offering alternative strategies for disease management.
In this podcast, Gilles Salles, MD, PhD, of the Memorial Sloan Kettering, New York, NY, Martin Hutchings, MD, PhD, of the Copenhagen University Hospital, Copenhagen, Denmark, Moshe Yair Levy, MD, of the Baylor Charles A. Sammons Cancer Center, Dallas, TX, Paolo Caimi, MD, of the University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, OH, and Nilanjan Ghosh MD, PhD, of the Levine Cancer Institute, Charlotte, NC, discuss the latest clinical updates on the use of antibody therapies for the treatment of NHL, as presented at the European Hematology Association (EHA) Congress 2021 and the International Conference on Malignant Lymphoma (ICML), 2021.
CAR-T in the CLL space
CAR T-cell therapy & multiple myeloma: past, present & future
Harnessing the tumor microenvironment in lymphoma therapy
Induction therapy in myeloma: an ever-changing paradigm
Precision epigenetic therapy for B-cell lymphoma
Acute leukemia: pushing boundaries in disease management
iwAL 2019: looking to the future of acute leukemia therapy
CAR T-cell therapy and precision medicine in non-Hodgkin lymphoma
MRD testing in multiple myeloma: new technology with promising clinical applications
CAR T-cells in myeloma: exploratory targets, payment models & treatment sequence
Patient discussion at EHA 2018: CAR T-cells and MRD in CLL
CLL therapies today: novel agents, combinations & the future of the field
CAR T-cell therapy: where are we now and what’s in store for the future?
Focus on MRD: current landscape and future questions in hemonc
Acute leukemias discussion: what does genomics and epigenomics tell us about patient management?
Acute leukemias: is MRD already a surrogate for survival?
Revolutionary immunotherapies for lymphoma
Latest advances and current challenges in immunotherapies for lymphoma
The circle of CLL: from gene discovery to targeted treatment
Debate on the use of MRD for multiple myeloma management
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive